Veteran biotech executive Tony Coles has been the man behind the curtain of two multibillion-dollar acquisitions and many more boardroom discussions.
But, publicly, he has arguably been just as active pushing the drug industry and other business leaders towards difficult conversations on corporate responsibility and race. Those conversations, he told the crowd at the STAT Summit in Boston Thursday, have been much more difficult.
Coles has spent the last several years making his voice heard on issues such as the importance of diversity and drug companies’ onus to patients. On stage a matter of weeks before the U.S. presidential election, he urged industry leaders not to grow jaded with debates over drug pricing and other kinds of legislation.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
